Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVRP.L Share News (VRP)

  • There is currently no data for VRP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS SUMMARY: Glencore Non-Executive Cuts Stake

Fri, 22nd May 2015 13:01

Director Dealings Summary - Week Ended May 22        
Company Name Position Number of Shares Resulting Holding *Note GBP Value
             
BUYS            
             
Topps Tiles Matthew Williams CEO 1 million 1.7 million   1,270,000
Countrywide Alison Platt CEO 41,700 41,700 Appointed CEO in September 2014. 248,000
Rank Group Henry Birch CEO 100,000 100,000 Same day as  Rank said it expects  full year results to meet management expectations.  205,000
Homeserve John Gibson Chairman 40,000 115,000 Day after reporting higher profit and said it would pay a special dividend of GBP97 million. 172,000
Sage Group Jonathan Howell Non-Executive Director 18,167 Undisclosed   103,000
AG Barr Stuart Lorimer CFO 14,000 1.1 million   87,000
Homeserve Ben Mingay Non-Executive Director 20,000 40,000 Day after reporting higher profit and said it would pay a special dividend of GBP97 million. 86,000
Inspired Capital Jeremy Coombes Interim CEO 535,000 2.9 million   75,000
Rank Group Clive Jennings CFO 25,000 25,000 Same day as  Rank said it expects  full year results to meet management expectations..  51,000
STM Group Michael Riddell Chairman 137,000 Undisclosed Week after STM said it made good start to 2015 and said trading so far this year is in line with its expectations. 49,000
Homeserve Stella David Non-Executive Director 10,450 28,138 2 days after reporting higher profit and said it would pay a special dividend of GBP97 million. 45,000
Mitchells & Butlers Eddie Irwin Non-Executive Director 10,000 30,000   45,000
Amara Mining John McGloin Chairman 271,249 1.6 million   41,000
McBride Chris Smith CFO 25,657 25,657 Appointed in January. 24,000
Oxford Biomedica Tim Watts CFO 194,174 5.8 million   19,000
Symphony Environmental Michael Stephen Deputy Chairman 151,000 933,998   15,000
Symphony Environmental Michael Laurier CEO 150,000 23 million   14,000
Verona Pharma David Ebsworth Chairman 300,000 3.6 million Week after Verona Pharma  posted a widened pretax loss for 2014. 11,000
Lekoil Greg Eckersley Non-Executive Director 50,000 2.8 million Week after Lekoil said its pretax loss narrowed as administrative and finance costs fell. 10,000
Oxford Biomedica Andrew Heath Non-Executive Director 100,000 1.1 million   10,000
Mortgage Advice Bureau Lucy Tilley CFO 4,500 4,500 Appointed in March. Was previously a director in Canaccord Genuity's corporate broking team, which worked on company's AIM listing. 9,900
Airea Roger Salt CFO 58,738 228,738   9,000
Symphony Environmental Ian Bristow CFO 100,000 1.2 million   9,000
K3 Business Technology Brian Davies CFO 2,253 9,537 Bought shares from CEO David Bolton 5,600
Verona Pharma Biresh Roy CFO 150,000 900,000 Week after Verona Pharma  posted a widened pretax loss for 2014. 5,000
Symphony Environmental Nirj Deva Chairman 50,000 363,925   4800
Verona Pharma Jan-Anders Karlsson CEO 135,000 2.9 million Week after Verona Pharma  posted a widened pretax loss for 2014. 4,700
Symphony Environmental Nicholas Clavel Non-Executive Director 50,000 550,000   4,500
             
SELLS            
             
Glencore William Macaulay Non-Executive Director 28 million 42 million Sold by FR Galaxy Holdings, an investment vehicle connected to Macaulay. 84,000,000
Moneysupermarket Simon Nixon Founder & non-executive deputy chairman 20 million 69.8 million The amount of shares sold is at the top end of the range. Credit Suisse, the sole bookrunner on the placing, said it would sell a stake of between 2.8% and 3.7% on behalf of Nixon, who retains a 12.8% holding. 56,000,000
Merlin Entertainments Nick Mackenzie Manager 440,000 1.5 million Same day as Merlin reported growth in revenue boosted by new site openings, features and good weather, as it continues strategic expansion plans. 2,000,000
Countrywide Grenville Turner Chairman 300,000 171,524   1,800,000
Hays Paul Venables CFO 750,000 953,014   1,200,000
Sthree Justin Hughes Corporate Executive Officer 267,500 390,867 Has sold parcels of shares in quick succession since May 12. 1,000,000
Euromoney Peter Ensor Chairman 20,421 175,918 Same day as interim ex-dividend date. 245,000
Bloomsbury Publishing Nigel Newton CEO 132,651 1.1 million Day after Bloomsbury posted a small rise in pretax profit and said trading in its current year has been good across all of its divisions. 232,000
ITV David Osborn HR Director 35,900 Nil   97,000
Rolls-Royce Jason Smith Divisional CEO 2,850 19,582   29,000
K3 Business Technology David Bolton CEO 2,253 994,961 Sold shares to CFO Brian Davies.  
             
*Note: A recent company event around the time of the dealing does not suggest the dealing took place because of that event.
When a spouse or related party to a director buys shares, the resulting holding is the beneficial holding of the director
             
Contact: +44 207 199 0340; newsroom@alliancenews.com; @AllNewsTeam      
             
Copyright 2015 Alliance News Limited. All Rights Reserved.        

More News
2 Mar 2018 15:01

BUZZ-Verona Pharma: Soars on positive data from mid-stage study

** British drug developer's U.S.-listed shares up 16 pct at $16.44 in morning trade - second highest gainer amongst Nasdaq-listed companies ** data a

Read more
18 Jan 2017 10:13

Verona Pharma Proposes Share Consolidation Amid Plans To List In US (ALLISS)

Read more
26 Sep 2016 09:39

Verona Pharma appoints sector veteran Morgan as CFO

(ShareCast News) - AIM listed drug development company Verona Pharma appointed sector veteran Piers John Morgan as chief financial officer on Monday, as the company prepares for clinical trials for its flagship drug. Chartered accountant Morgan has 25 years' financial experience and was previously c

Read more
13 Sep 2016 12:04

Verona Pharma makes progress on new respiratory drug

(ShareCast News) - Verona Pharma, a UK based drug development company focused on first-in-class medicines to treat respiratory diseases, reported positive results on new drug "RPL554". The company's lead drug, RPL554, is a first-in-class drug currently in Phase 2 trials as a nebulized maintenance tr

Read more
20 Jun 2016 15:02

UK Shareholder Meetings Calendar - Next 7 Days

Read more
20 Jun 2016 12:50

Verona Pharma secures funding for drug trial

(ShareCast News) - Shares in AIM-listed Verona Pharma rallied on Monday as the drug development company it had successfully secured funding commitments to raise gross proceeds of around £44.7m through a conditional placing that was significantly oversubscribed. Net proceeds from the placing with new

Read more
20 Jun 2016 11:06

LONDON MARKET MIDDAY: Receding Brexit Fear Lifts Stocks And Pound

Read more
20 Jun 2016 09:40

WINNERS & LOSERS SUMMARY: Cat Allergy Disappointment Sinks Circassia

Read more
17 Jun 2016 16:09

Verona Pharma To Raise GBP44.7 Million In Share Placing (ALLIS)

Read more
3 Jun 2016 12:52

Verona Pharma's shares fall as higher R&D costs widen FY loss

(ShareCast News) - Shares in Verona Pharma sagged more than 8% as it turned in a wider full-year pre-tax loss of £8.9m, from a loss of £3.8m, thanks to higher research and development more than doubling. Chief executive Jan-Anders Karlsson said Verona had made substantial clinical progress with its

Read more
3 Jun 2016 06:59

Verona Pharma Loss Widens On Higher Research And Development Costs

Read more
10 May 2016 08:11

Verona Pharma Gets Positive Results From COPD Treatment Study

Read more
15 Mar 2016 10:35

Verona Pharma excites with asthma trial results

(ShareCast News) - Verona Pharma has published further encouraging clinical results for its RPL554 drug to treat chronic obstructive pulmonary disorder (COPD). Tests among asthma patients found the inhaled drug, which has both bronchodilator and anti-inflammatory properties in the same active molecu

Read more
21 Jan 2016 13:31

DIRECTOR DEALINGS: Verona Pharma Chairman Ups Interest

Read more
11 Jan 2016 08:45

Verona Pharma Chief Financial Officer Biresh Roy Leaving Company

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.